Caplacizumab (Cablivi)
Revision as of 19:42, 27 February 2020 by Warner-admin (talk | contribs) (Text replacement - "Category:Antibody medications" to "")
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi